All filters
Slidesets
Clinical evolution of porphyria cutanea tarda (PCT) in HCV monoinfected and HIV/HCV co-infected patients after viral eradication with direct acting agents (DAA)- P. Rodriguez Cortes
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Relapse or reinfection of hepatitis C after direct acting antiviral treatment: unravelled by phylogenetic analysis. Results from the Spanish GEHEP-004 cohort - L. Cuypers
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Acute hepatitis A outbreak among men who have sex with men in Milan: the role of HIV co-infection- M. Merli
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Outbreak of hepatitis A in men who have sex with men in 2017 - Experience in an infectious diseases department, Hospital de Curry Cabral - CHLC, Lisbon, Portugal- A.R. Garrote
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Direct acting antiviral treatment for HCV in safety net settings: Provider and HIV/HCV co-infected patient preferences- M. Peters
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Non liver and survival benefits of SVR in HCV - Marion Peters, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
The use of HIV+ or HCV+ organs in transplantation- Stefano Fagiuoli, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Case based debate: Is HCC increased with DAA therapy? Con stance- Nicolás Merchante, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Case based debate: Is HCC increased with DAA therapy? Pro stance- Douglas Dieterich, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Antifibrotics and fatty liver drugs in the pipeline- Sanjay Bhagani, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Hepatic steatosis AND Lipid proFile evolution After Hepatitis C treatment in HCV/HIV coinfected patients- J. Méndez
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Treatment of cirrhotic HCV/HIV co-infected patients with DAAs- R. Sarmento e Castro
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
Regression of liver fibrosis in patients with chronic hepatitis C treated with direct acting anti-viral (DAA) therapy in the country of Georgia- E. Dolmazashvili
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
HCV elimination program in Georgia: Successes and challenges- Nikoloz Chkhartishvili, MD, MS, PhD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
What challenges remain in viral hepatitis- Jürgen Rockstroh, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
NASH and NAFLD in HIV: same or different? - Mariana Machado, MD
Presented at:
International Workshop on HIV & Hepatitis Co-infection 2017
Slidesets
WHO Target 90-90-90 : Achievable for Latin America- Alejandro Afani, MD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
HIV in Latin America: 35 years later- Marcelo Wolff, MD, FACP, FIDSA
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Difficult to reach populations in Latin America- Ana Paulina Celi de la Torre, MD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
New approaches for preventing transmission- Charles Boucher, MD, PhD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
State-of-the-art lecture on PrEP- Mauro Schechter, MD, PhD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Proviral DNA as a Target for HIV-1 Resistance Analysis- Dr. Lara
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Transmitted Drug Resistance in HIV-Infected Treatment-Naïve Patients in Chile between 2014 and 2017- Dr. Palma
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017
Slidesets
Clinical Implications of low level viremia/ failure and resistance- Francesca Ceccherini– Silberstein, PhD
Presented at:
Andean Pacific Workshop on HIV & Hepatitis 2017